Top quality Obeticholic Acid with best price CAS 459789-99-2
6-ECDCA;Ocaliva;6-Ethylchenodeoxycholic acid;6α-ethyl-chenodeoxycholic acid
Obeticholic acid CAS:459789-99-2 is a synthetically modified bile acid and potent agonist of the farnesoid X nuclear receptor (FXR) that is used to treat liver diseases including primary biliary cholangitis. Obeticholic acid has not been linked to elevations in serum enzyme levels during therapy, but has been linked to an increased rate of severe liver related adverse events such as ascites, jaundice and liver failure.
Obeticholic acid CAS:459789-99-2 is a dihydroxy-5beta-cholanic acid that is chenodeoxycholic acid carrying an additional ethyl substituent at the 6alpha-position. A semi-synthetic bile acid which acts as a farnesoid X receptor agonist and is used for treatment of primary biliary cholangitis. It has a role as a farnesoid X receptor agonist and a hepatoprotective agent. It is a dihydroxy-5beta-cholanic acid, a 3alpha-hydroxy steroid and a 7alpha-hydroxy steroid. It derives from a chenodeoxycholic acid.
Obeticholic acid CAS:459789-99-2 is a potent and selective farnesoid X receptor (FXR) agonist with EC50 of 99 nM. It reduced liver fat and reverted cholestasis in a rat model. Obeticholic acid is currently being considered for FDA approval to treat fibrosis caused by non-alcoholic liver steatohepatitis (NASH). The NDA from Intercept Pharmaceuticals was approved in November 2019 and obeticholic acid is expected to be granted full approval for this indication in 2020.